A PYMNTS Company

US: FTC clarifies rules of pharma patent buyouts

By  |  November 6, 2013

The US Federal Trade Commission has reportedly issued its final amendments to legislation outlining the requirements of companies that acquire pharmaceutical patents to report that acquisition to the FTC and the Department of Justice, according to reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The regulator has clarified when such deals need to be notified under the premerger notification program. According to reports, the FTC and DOJ worked together to amend the current guidelines that will now become effective 30 days following publication.

    Full content: 4-Traders

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.